ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. increased its position in shares of ADMA Biologics, Inc. (NASDAQ:ADMAFree Report) by 17.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 158,634 shares of the biotechnology company’s stock after acquiring an additional 23,844 shares during the quarter. Principal Financial Group Inc. owned approximately 0.07% of ADMA Biologics worth $717,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in ADMA Biologics by 87.7% during the third quarter. GSA Capital Partners LLP now owns 242,284 shares of the biotechnology company’s stock worth $867,000 after acquiring an additional 113,184 shares during the last quarter. Qube Research & Technologies Ltd boosted its position in ADMA Biologics by 22.9% during the third quarter. Qube Research & Technologies Ltd now owns 1,204,648 shares of the biotechnology company’s stock worth $4,313,000 after acquiring an additional 224,696 shares during the last quarter. American Century Companies Inc. boosted its holdings in shares of ADMA Biologics by 20.8% in the 3rd quarter. American Century Companies Inc. now owns 4,892,123 shares of the biotechnology company’s stock valued at $17,514,000 after purchasing an additional 840,761 shares during the last quarter. Aigen Investment Management LP acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at $140,000. Finally, SG Americas Securities LLC boosted its holdings in shares of ADMA Biologics by 417.3% in the 4th quarter. SG Americas Securities LLC now owns 93,236 shares of the biotechnology company’s stock valued at $421,000 after purchasing an additional 75,213 shares during the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Insider Activity

In related news, Director Steve Elms sold 183,008 shares of ADMA Biologics stock in a transaction on Friday, March 15th. The shares were sold at an average price of $6.01, for a total transaction of $1,099,878.08. Following the sale, the director now owns 2,577,387 shares of the company’s stock, valued at approximately $15,490,095.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders have sold 639,895 shares of company stock valued at $3,927,169. Company insiders own 3.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ADMA shares. Mizuho lifted their price target on shares of ADMA Biologics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Friday, May 10th. HC Wainwright lifted their price target on shares of ADMA Biologics from $7.50 to $10.00 and gave the company a “buy” rating in a report on Friday, May 10th. Raymond James lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company a “strong-buy” rating in a report on Friday, May 10th. Finally, Cantor Fitzgerald lifted their price target on shares of ADMA Biologics from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Friday, May 10th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $10.50.

Check Out Our Latest Stock Analysis on ADMA

ADMA Biologics Stock Performance

Shares of ADMA stock opened at $9.55 on Monday. The company’s fifty day simple moving average is $7.37 and its 200-day simple moving average is $5.77. ADMA Biologics, Inc. has a 52 week low of $3.06 and a 52 week high of $9.77. The company has a current ratio of 5.21, a quick ratio of 1.86 and a debt-to-equity ratio of 0.91. The company has a market cap of $2.21 billion, a PE ratio of -477.50 and a beta of 0.43.

ADMA Biologics (NASDAQ:ADMAGet Free Report) last issued its earnings results on Thursday, May 9th. The biotechnology company reported $0.08 EPS for the quarter, beating analysts’ consensus estimates of $0.05 by $0.03. ADMA Biologics had a negative net margin of 1.29% and a positive return on equity of 17.24%. The business had revenue of $81.90 million for the quarter, compared to the consensus estimate of $77.28 million. During the same quarter last year, the firm posted ($0.03) EPS. The business’s revenue for the quarter was up 43.9% compared to the same quarter last year. As a group, equities research analysts anticipate that ADMA Biologics, Inc. will post 0.35 EPS for the current year.

ADMA Biologics Company Profile

(Free Report)

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

Further Reading

Want to see what other hedge funds are holding ADMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ADMA Biologics, Inc. (NASDAQ:ADMAFree Report).

Institutional Ownership by Quarter for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.